TNNT2 and cardiomyopathy: This revealed that transcriptomic changes directly correlate with sarcomere function and can be used to predict TNNT2 variant pathogenicity, indicating that reclassification of TNNT2 variants would improve cardiomyopathy risk determination and treatment responses in patients with these variants.